DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Lucitanib is an investigational drug.
There have been 7 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Breast International Group.
There are eleven US patents protecting this investigational drug and ninety-five international patents.
Recent Clinical Trials for Lucitanib
|A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor||Bristol-Myers Squibb||Phase 1/Phase 2|
|A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor||Clovis Oncology, Inc.||Phase 1/Phase 2|
|A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)||Immunomedics, Inc.||Phase 1/Phase 2|
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lucitanib||Start Trial||Human anti-VEGFR-2/KDR antibodies||KADMON CORPORATION, LLC (New York, NY)||Start Trial|
|Lucitanib||Start Trial||Rho kinase inhibitors||KADMON CORPORATION, LLC (New York, NY)||Start Trial|
|Lucitanib||Start Trial||Rho kinase inhibitors||Kadmon Corporation, LLC (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|